Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluoxetine + topiramate
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination involves **fluoxetine**, a selective serotonin reuptake inhibitor (SSRI) used primarily for treating depression, bulimia, and other psychiatric disorders, and **topiramate**, an anticonvulsant used for epilepsy and migraine prevention. The combination has been studied for its potential in managing eating disorders and promoting weight loss, particularly in morbidly obese patients before bariatric surgery.
02
Targets
CACNA1E (Voltage-dependent R-type calcium channel subunit alpha-1E)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on fluoxetine + topiramate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluoxetine + topiramate.